SciELO - Scientific Electronic Library Online

 
vol.24 número4Factores de riesgo de contagio de la Covid-19 en personal sanitarioMetodología para evaluar la exposición ocupacional a contaminantes químicos en altitud índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Archivos de Prevención de Riesgos Laborales

versión On-line ISSN 1578-2549

Resumen

SABATER-VIDAL, Susana et al. Vaccine response to SARS-CoV-2 in hospital workers. Arch Prev Riesgos Labor [online]. 2021, vol.24, n.4, pp.383-403.  Epub 17-Ene-2022. ISSN 1578-2549.  https://dx.doi.org/10.12961/aprl.2021.24.04.05.

Introduction:

The aim of this study was to measure anti-SARS-CoV-2 immunity of hospital workers after a completed 2-dose Pfizer-BionTech vaccination, and to examine factors potentially associated with immunity status. Side effects of the vaccine were also studied.

Method:

This was a cross-sectional study of a representative sample of General University Hospital of Castellon workers, vaccinated with two doses in January and February 2021. We measured IgG antibodies against protein N (IgG-NP), IgM against protein S (IgM-S), and quantitative levles of IgG against protein S (IgG-Quant) one month after the last dose. We obtained information on demographic, risk factors, and vaccine side effects via a self-completed questionnaire. For the statistical analysis we used multiple regression models.

Results:

Two hundred seventy-five workers participated (96.8%, 275/284). Positive IgG-Quant, IgM-S, and IgG-NP were 99.6%, 14.9% and 4.4%, respectively. Adjusted IgG-Quant levels increased significantly with obesity, nonsmoking status, positive IgM-S, and/or IgG-NP. The prevalence of IgM-S was higher in males, and associated with the same factors as those for IgG-Quant. Among those with a history of COVD-19 infection, 42.9% did not have IgG-NP. Overall 86.5% of participants had side effects, which were associated with positive IgG-NP, high IgG-Quant levels, younger age, and being female.

Conclusions:

All but one participant developed immunity. Those who had suffered from COVID-19 infection had higher antibody levels. A high proportion of participants had mild secondary effects, especially those with previous COVID-19 infection.

Palabras clave : SARS-CoV-2; COVID-19; Pfizer-BionTech vaccine; IgG-Quant; IgM-S; IgG-NP; body mass index; obesity; no-smokers; adverse effects.

        · resumen en Español     · texto en Español     · Español ( pdf )